Kalyani Meditimes Profile
Key Indicators
- Authorised Capital ₹ 6.20 Cr
as on 25-06-2024
- Paid Up Capital ₹ 5.90 Cr
as on 25-06-2024
- Company Age 8 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 825.00%
(FY 2022)
- Profit -45.45%
(FY 2022)
- Ebitda -35.11%
(FY 2022)
- Net Worth -179.24%
(FY 2022)
- Total Assets -18.91%
(FY 2022)
About Kalyani Meditimes
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 6.20 Cr and a paid-up capital of Rs 5.90 Cr, as per Ministry of Corporate Affairs (MCA) records.
Bhaskar Cherukupalli, Satya Kammila, and Krish Ramesh serve as directors at the Company.
- CIN/LLPIN
U74999TN2016PTC111701
- Company No.
111701
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jul 2016
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Kalyani Meditimes?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Krish Ramesh  | Director | 28-Jul-2016 | Current |
| Bhaskar Cherukupalli | Director | 29-Sep-2021 | Current |
| Satya Kammila | Director | 29-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Kalyani Meditimes.
Kalyani Meditimes Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 825% increase. The company also saw a substantial fall in profitability, with a 45.45% decrease in profit. The company's net worth observed a substantial decline by a decrease of 179.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Kalyani Meditimes?
In 2020, Kalyani Meditimes had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Madhukar Gangadi Ventures Private LimitedActive 5 years 8 months
Bhaskar Cherukupalli is a mutual person
- Lone Furrow Investments Private LimitedActive 4 years 1 month
Bhaskar Cherukupalli is a mutual person
- Wynclark Pharmaceuticals Private LimitedActive 17 years 10 months
Bhaskar Cherukupalli and Satya Kammila are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Kalyani Meditimes?
Kalyani Meditimes has a workforce of 12 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kalyani Meditimes, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kalyani Meditimes's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
